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The genetics of late-onset Alzheimer’s disease (LOAD) has taken impressive steps forwards in the last few years. To date, more
than six-hundred genes have been linked to the disorder. However, only a minority of them are supported by a suﬃcient level
of evidence. This review focused on such genes and analyzed shared biological pathways. Genetic markers were selected from a
web-based collection (Alzgene). For each SNP in the database, it was possible to perform a meta-analysis. The quality of studies
was assessed usingcriteria such as size of research samples,heterogeneity across studies,and protection from publication bias. This
produced a list of 15 top-rated genes: APOE, CLU, PICALM, EXOC3L2, BIN1, CR1, SORL1, TNK1, IL8, LDLR, CST3, CHRNB2,
SORCS1, TNF, and CCR2. A systematic analysis of gene ontology terms associated with each marker showed that most genes were
implicated in cholesterol metabolism, intracellular transport of beta-amyloid precursor, and autophagy of damaged organelles.
Moreover, the impact of these genes on complement cascade and cytokine production highlights the role of inﬂammatory
response in AD pathogenesis. Gene-gene and gene-environment interactions are prominent issues in AD genetics, but they are
not speciﬁcally featured in the Alzgene database.
1.Introduction
Alzheimer’s disease (AD) is the leading cause of dementia
in developed countries. It aﬄicts 5.3 million individuals in
the US. Total direct and indirect cost is US$ 172 billion
per year [1]. The prevalence of AD shows an age-dependent
progression in the elderly. Thus, approximately 5% of all
persons over age 70 have AD (late-onset AD, LOAD); this
proportion raises to 25%–45% in “oldest old” (>85 years)
individuals. About 10% of AD patients develop symptoms
before age 65, more often in their 40s or 50s [1].
Clinically, AD is characterized by progressive impair-
ments in memory and other cognitive domains. Behavioral
and psychiatric symptoms (BPSDs), clustered into agita-
tion/aggression, mood disorders, and psychosis, may occur
with disease progression [2]. Neuroimaging studies display
atrophy in the cerebral cortex and the hippocampus of AD
brain [3, 4] .Am a r k e dn e u r a ll o s si sr e p o r t e di nc h o l i n e r g i c
nuclei in the basal forebrain as opposed to an overac-
tivation of NMDA-mediated glutamatergic pathways [5].
Postmortem examination reveals the neuropathological hall-
marks of AD that include neuritic plaques, neuroﬁbrillary
tangles (NFTs), and amyloid angiopathy [6]. Neuritic pla-
ques are extracellular aggregates of beta(β)-amyloid protein
in a milieu of reactive astrocytes and activated microglia.
NFTs are intraneuronal cytoplasmatic ﬁlaments composed
of hyperphosphorylated tau, frequently conjugated with
ubiquitin. Pathophysiologically, researchers assign a pivotal
role to beta-amyloid deposition in the brain [6]. Beta-
amyloidpeptidesarederivedfromproteolyticactivityofpro-
teinases (β and γ secretases) on amyloid precursor protein
(APP). Study performed in transgenic animals suggest that
neuroinﬂammation plays an important role in the process
of cerebral amyloid deposition [7]. It has been shown that2 International Journal of Alzheimer’s Disease
inﬂammatory cytokines such as interleukin (IL)-1β,I L - 6 ,
tumor necrosis factor-αgTNF-α), or IFN gamma can aug-
ment APP expression and Aβ formation [8, 9]. It was also
reported that nonsteroidal anti-inﬂammatory drugs are able
to transcriptionally upregulate β-secretase mRNA, protein
and enzymatic activity [10]. Intraperitoneal injection of
lipopolysaccharide induced memory impairment in mice
associated with amyloidogenesis [11]. On the other hand,
recent lines of evidence indicate that blood-borne mononu-
clear phagocytes are capable of inﬁltrating the brain and
restricting beta-amyloid plaques, thereby, limiting disease
progression. Indeed, there would be two types of monocytes.
M1 has proinﬂammatory eﬀects detrimental to AD brain.
Alternately, M2 macrophages are recruited to noninﬂamed
tissues and are believed to be highly phagocytic, anti-
inﬂammatory eﬀector cells. They could clear beta amyloid
via phagocytosis [12]. APP follows a complex intracellular
traﬃcking pathway that inﬂuences its processing to either a
soluble fragment (sAPPα) or to sAPPβ and the insoluble Aβ
[13]. The cleavage of APP to generate pathological Aβ may
occurwhenAPPtransitsfromtheendosometothelysosome.
This is associated with APP gene mutations, whereas wild
APP has rapid and direct transport from the cell surface to
the lysosomes [14]. APP traﬃcking is regulated by sorting-
protein-related receptor (sorLA), which binds the APP in the
Golgi reducing the availability of precursors for transport,
cleavage, and transformation into Aβ [15, 16]. Over the last
few years, a shift occurred in research focus from amyloid
deposition to tauopathy. The physiological function for
protein tau is binding to and stabilization of microtubules.
Microtubules ensure cell shape and constitute roads of
transport. Microtubule-dependent transport is ensured by
families of motor proteins dyneins and kinesins, respectively,
for retrograde transport from distal processes towards soma
and as plus-end directed motor for anterograde transport.
The eﬀect of protein tau on transport appears to be dual.
First, hyperphosphorylation can cause protein tau to detach
from the microtubules and decrease its ability to control
microtubule dynamics. On the other hand, increased levels
of protein tau can saturate microtubules and hinder the
“foot-stepping” of the motor proteins needed for axonal and
dendritic transport. Both aspects of tau-related transport
deﬁcits have been observed and both can ﬁt into a model
leading to “starving synapses” that eventually culminates in
neuronal death [17, 18]. It is acknowledged that 75% of
people with AD have sporadic AD. This is most likely a
multifactorial condition, which involves a combination of
genetic, lifestyle, and environmental factors. 25% is familial
AD (FAD). Early-onset AD encompasses 5% of FAD cases.
Early-onset FAD is inherited in an autosomal dominant
manner and is caused by mutations in one of these three
genes: APP, PSEN1, and PSEN2. As for LOAD, the only
established genetic factor is apolipoprotein E (APOE). The
APOE gene is at chromosome location 19q13.2. APOE-
associated Alzheimer’s disease is due to a speciﬁc variation
in the APOE gene called e4 allele. It is estimated that 40–
65% of AD patients have at least one copy of the e4 allele
[19]. Individuals with two e4 alleles have up to 20 times the
risk of developing AD [19]. Another variant of the APOE
gene,e2,hasprotectiveeﬀectsagainstthedevelopmentofAD
[20, 21]. Nonetheless, a third of patients with AD are ApoE4
negative, and some ApoE4 homozygotes never develop the
disease. Since the early 90s, more than six hundred genes
have been investigated as susceptibility factors for LOAD
(http://www.Alzgene.org/). We reviewed the best established
LOAD genes and suggested a method to identify shared
biological pathways.
2. Methods
We used the AlzGene database to identify those genes that
had the strongest association with LOAD, for which there
was a qualitatively high level of evidence. AlzGene is a
web-based synopsis of published association studies on AD
[22]. AlzGene is regularly updated by studies retrieved from
peer-reviewed journals and available in English language.
Authors are encouraged to submit their data as soon as their
work is accepted for publication. Data presented only in
abstract form are not included. For all polymorphisms with
minor allele frequencies in healthy controls >1%, and for
which case-control genotype data are available in at least
four independent samples, a meta-analysis is performed.
Summary OR and 95 percent CIs are calculated using the
DerSimonian and Laird random-eﬀects model [23]. Genes
which contain variants showing at least one signiﬁcant
OR in meta-analysis are included in a “Top Results” list.
To establish their ranking, each positive meta-analysis is
graded according to human genome epidemiology network
(HuGENet) interim criteria for the assessment of cumulative
evidence of genetic associations [24]. These criteria take into
account the amount of evidence (sample size, measured as
total number of minor allelesof casesand controlscombined
in the meta-analysis “N minor”; grade A: N minor exceeds
1,000; grade B: N minor is between 100 and 1,000; grade C:
N minor is <100), consistency of replication (heterogeneity
across studies, measured as I2; grade A: I2 point estimates
<25%; grade B: between 25% and 50%; grade C: >50%)
and protection from bias (the following potential reasons
for bias in the meta-analysis results are assessed: summary
OR < 1.15 (low OR); loss of signiﬁcance after exclusion
of ﬁrst study; loss of signiﬁcance after exclusion of studies
with deviations from HWE in control groups; evidence for
publication bias; grade A: no bias; grade B: no demonstrable
bias, but important information is missing for its appraisal;
grade C: evidence for clear bias that can invalidate the
association). Overall epidemiologic credibility is graded as
“A” (= strong) if associations received three A grades, “B”
(= moderate) if they received at least on B grade but no C
grades, and “C” (= w e a k )i ft h e yr e c e i v e daCg r a d ei na n y
of the three assessment ﬁelds. Loci with the same grade are
ordered by P-value.
Genes with strong (A) and moderate (B) associa-
tions were included in a query set of the gene ontology
database AmiGO to discover shared biological functions.
T h eG e n eO n t o l o g y [ G O( http://www.geneontology.org/);
Gene Ontology Consortium, 2000] project develops struc-
tured controlled vocabularies, or ontologies, to describeInternational Journal of Alzheimer’s Disease 3
fundamental characteristics of genes and their products
in a species-independent manner. Members of the GO
consortium submit annotations made using these ontologies
to the GO database for integration and dissemination.
AmiGO (version 1.7) (http://amigo.geneontology.org/)i s
a web-based application that allows users to search, sort,
analyze, visualize, and download data about gene ontologies
and products [25]. Ontologies are clustered into three
categories: (1) biological process: any process speciﬁcally
pertinent to the functioning of integrated living units: cells,
tissues, organs, and organisms. A process is a collection of
molecular events with a deﬁned beginning and end; (2)
cellular component: the part of a cell or its extracellular
environment in which a gene product is located. A gene
product may be located in one or more parts of a cell,
and its location may be as speciﬁc as a particular macro-
molecular complex, that is, a stable, persistent association
of macromolecules that function together. (3) Molecular
function: elemental activities describing the actions of a gene
product at the molecular level. A given gene product may
exhibit one or more molecular functions. The GO “Term
Enrichment” tool, which determines whether the observed
l e v e lo fa n n o t a t i o nf o rag r o u po fg e n e s( t e s td a t a s e t )i s
signiﬁcant in the context of a background set, was useful
for discovering relationships between genes. We included
LOAD genes in test dataset; the UniProt Knowledgebase
(UniProtKB: http://www.uniprot.org/), a large collection of
gene products, was used as comparison dataset. Signiﬁcant
annotations were associated with at least two genes and
more represented in test dataset (P = 0.003 after Bonferroni
correction). Subsequently, the GO slimmer tool enabled
to remap granular, speciﬁc annotations up to a user-
speciﬁedsetofhigh-levelterms.Weexcludedtermsthatwere
nonspeciﬁc (e.g., “biological regulation”) or shared by less
than three genes. Synonymous annotations (e.g., “cell death”
and “regulation of cell death”) were collapsed into one term.
3. Results
The Alzgene database (updated 13 September 2010) includes
1,380 studies and 666 genes. The number of meta-analyses is
380.
3.1. Top Genes Associated with LOAD. Forty-two genes have
at least one positive meta-analysis (see Table 1). Of them,
ﬁ f t e e na r es u p p o r t e db ya na d e q u a t el e v e lo fe v i d e n c e( “ A ”
or “B” grade on overall association credibility). These genes
are reported below (meta-analysis results are referred to the
best SNP for each gene).
APOE. The gene encoding apolipoprotein E (chromosome
19q13.2)wasassociatedwithADinthirty-eightcase-control
samples (Caucasian = 28; Asian = 4; African descent = 2;
Hispanic descent = 1; mixed ethnic groups = 3) and four
family-based studies. Overall OR was 3.77 (95% CI 3.29–
4.32; I2 = 13) in Caucasian samples and 3.99 (95% CI: 2.86–
5.57 I2 = 20) in Asian samples.
CLU. Clusterin (apolipoprotein J) is a chaperone molecule
that appears to be involved in membrane recycling and
apoptosis. Clusterin, like apolipoprotein E, is found in
amyloid plaques [26]. Clusterin interacts with the soluble
form of beta amyloid in animal models of AD and binds
soluble beta-amyloid in a speciﬁc and reversible manner,
forming complexes that cross the blood-brain barrier [27].
The gene-encoding clusterin CLU (chromosome 8) was
investigated as a susceptibility factor for LOAD in genome-
wide association studies (GWASs) [28–32]a sw e l la sc a n -
didate gene studies [33, 34]. Meta-analytic data reveal four
polymorphisms consistently associated with LOAD. The
best SNP is rs11136000 (Caucasian subjects; N minor =
53,712; OR 0.88 95% CI: 0.86–0.91). Valproic acid has been
recently demonstrated to stimulate clusterin expression [35].
Plasma levels of clusterin have been recently associated with
atrophy of the entorhinal cortex, baseline disease severity,
and rapid clinical progression in AD [36]. These ﬁndings
should prompt further investigations to ascertain the impact
o fC L Uo nA Dp h e n o t y p e s .
PICALM. Phosphatidylinositol-binding clathrin assembly
proteins is a key component of clathrin-mediated endocy-
tosis. It recruits clathrin and adaptor protein 2 (AP-2) to the
plasma membrane and, along with AP-2, recognizes target
protein. The attached clathrin triskelions cause membrane
deformation around the target proteins enclosing them
within clathrin-coated vesicles [37]. Of relevance to AD,
PICALM appears to be involved in VAMP2 traﬃcking, a
process that is crucial to the functional integrity of synapses.
[38]. AD brains show a reduced number of synapses, and
this reduction could correlate to cognitive defects better than
the accumulation of plaques and tangles [39]. Alternatively,
APP is processed in endocytotic compartments [40]; thus
PICALM could promote the synthesis of beta amyloid by
regulatingendocytosis.ThePICALM gene(chromosome11)
was analyzed in seven case-control samples [29–31, 33, 41,
42]. Overall PICALM was investigated in 10,251 patients and
18,270 controls. Two SNPs were associated with LOAD. The
best one is rs3851179 (Caucasian subjects; N minor = 44,358
OR 0.88 95% CI: 0.85–0.91).
EXOC3L2. Exocyst complex component 3-like 2 is also
involved in vesicle targeting during exocytosis of proteins
and lipids that is essential to neuron outgrowth and integrity
[43]. Seshadri et al. [30]r e p o r t e da na s s o c i a t i o nb e t w e e n
the EXOC3L2 gene and LOAD in their multisample GWAS
which included 1,140 patients and 1,210 controls (rs597668
N minor = 13,519 OR 1.17 95% CI: 1.12–1.23).
BIN1. Bridging integrator 1 is a member of the BAR adapter
family which has been implicated in endocytosis and intra-
cellular endosome traﬃcking [44, 45]. In addition, bin1 is
crucialforthefunctionofpathwaysleadingtocellsenescence
and apoptosis [46–48]. The BIN1 gene (chromosome 2)
was investigated in four case-control samples [29, 30, 41]
consisting of 4,473 patients and 7,659 controls. A meta-
analysisshowedthatBIN1rs744373SNPwasassociatedwith
LOAD (N minor = 24,713 OR 1.15 95% CI: 1.10 1.20).
CR1. Complement component receptor 1 regulates com-
plement cascade via the inhibition of both classical and4 International Journal of Alzheimer’s Disease
Table 1: Top-rated genes associated with LOAD.
Gene Ch N◦ minor Quality
(HuGENet)
Caucasian
OR
Asian
OR
All ethnic groups
OR
APOE 19 4,167 AAA 3.77 (3.29–4.32) 3.99 (2.86–5.57) 3.61 (3.20–4.08)
CLU 8 53,712 AAA 0.87 (0.85–0.90) n.a 0.88 (0.86–0.91)
PICALM 11 44,358 AAA 0.89 (0.86–0.92) n.a 0.90 (0.86–0.93)
EXOC3L2 19 13,519 AAA 1.17 (1.12–1.23) n.a 1.17 (1.12–1.23)
BIN1 2 24,713 AAA 1.14 (1.08–1.21) n.a 1.14 (1.08–1.21)
CR1 1 18,779 AAA 1.14 (1.08–1.20) n.a 1.16 (1.09–1.22)
SORL1 11 1,734 AAA 1.07 (1.00–1.15) 1.30 (1.13–1.50) 1.10 (1.02–1.17)
TNK1 17 3,538 AAA 0.84 (0.76–0.93) n.a 0.84 (0.76–0.93)
IL8 4 1,157 AAA 1.26 (1.01–1.58) n.a 1.26 (1.01–1.58)
LDLR 19 1,228 AAA 0.85 (0.72–0.89) n.a 0.85 (0.72–0.89)
CST3 20 1,203 AAA 1.28 (1.04–1.56) n.a 1.23 (1.03–1.48)
CHRNB2 1 227 BAA 0.69 (0.51–0.95) n.a 0.67 (0.50–0.90)
SORCS1 10 567 BAA 1.34 (1.09–1.65) n.a 1.34 (1.09–1.65)
TNF 6 301 BAA n.a 1.37 (1.05–1.79) 1.35 (1.39–1.77)
CCR2 3 308 BAA 0.73 (0.56–0.97) n.a 0.73 (0.56–0.97)
OR values are referred to the best SNP for each gene.
n.a: one study or none; meta-analysis could not be performed.
HuGENet classiﬁcation was used to assess the quality of studies (see text).
alternative pathway C3 and C5 convertases [49]. Notably,
complement inhibition was shown to reduce the clearance
of beta amyloid in animal models [50]. More recently, cr1
has been found to bind peripheral blood beta amyloid in
a complement C3b-dependent manner, a mechanism that
is implicated in the clearance of pathogens and proteins
from the bloodstream. Levels of beta amyloid targeted by
this pathway diﬀered signiﬁcantly in AD compared to mild
cognitive impairment and nondemented elderly controls
[51]. The gene encoding cr1, chromosome 1 (CR1), was
investigated in eleven independent samples [28, 29, 31, 33,
41, 42, 52]. Overall sample included 13,193 cases and 20,551
controls. Meta-analytic data showed the association between
CR1 rs3818361 and LOAD in Caucasian subjects (N minor =
18, 779 OR 1.14 95% CI: 1.08 1.20).
SORL1. Sortilin-related receptor (SorLA) is a sorting recep-
tor that regulates traﬃcking and processing of APP. SorLA
acts as a retention factor for APP in trans-Golgi com-
partments/trans-Golgi network, preventing the release of
the precursor into regular processing pathways [16, 53]. In
addition, SorLA is an apolipoprotein E receptor (LR11). The
gene-encoding SorLA, SORL1, was investigated as a suscep-
tibility factor for LOAD in twenty-one case-control samples
[54–74].NineSNPsweresigniﬁcantlyassociatedwithLOAD.
The best one is rs2282649 (N minor = 1,734 OR 1.10 95%
CI: 1.02–1.17). A recent study has suggested that the role of
SORL1 as a LOAD gene might be gender dependent, consis-
tentlydemonstratedinwomen[67].Weconﬁrmedthisresult
in a sample of AD patients attending our center in Athens.
In addition, we reported correlations between SORL1 SNPs,
psychosis, and proinﬂammatory cytokines [75].
TNK1. Nonreceptor tyrosine kinase 1 is involved in intra-
cellular transduction pathways, and it was shown to enable
TNF-alpha-induced apoptosis [76]. One polymorphism
(rs1554948) in the TNK1 gene (chromosome 17) was
investigated in ﬁve samples [77], and it proved its association
with LOAD (rs1554498; N minor = 3,538; OR 0.84 95% CI:
0.76–0.93).
IL8. Interleukin 8 is a proinﬂammatory cytokines. Cere-
brospinal ﬂuid levels of IL-8 were found to be increased in
AD and mild cognitive impairment [78]. IL-8 production
can be enhanced by beta amyloid [79]. The gene-encoding
IL-8(chromosome4)wasanalyzedinfourcase-controlsam-
ples[32,80–82],including660patientsand933controls,and
it proved to be signiﬁcantly associated with LOAD (rs4073;
N minor = 1,157; OR 1.27 25%CI: 1.08–1.50). IL8 showed
gene-gene interactions with the methylenetetrahydrofolate
reductase (MTHFR) [82] and interleukin-1alpha (ILalpha)
[80] genes. Metal ions (zinc; copper) appear to play an
important role in AD pathophysiology. For instance, the
provision of a zinc-enriched diet was found to enhance
Alzheimer-like spatial memory impairments in transgenic
mice and to modify hippocampal deposits of amyloid
plaques [83]. Zinc ions promote beta-amyloid aggregation
leadingtoconformationalchanges[84].Aconsistentamount
of evidence links zinc and IL8 pathways. Zinc deﬁciency
increases the expression of cytokine-related genes (TNF;
IL1B; IL8) in leukemia cell-lines. Elevated levels of pro-
inﬂammatory cytokines including IL-8 were reported in a
group of healthy old subjects coupled with low circulating
levels of zinc [85]. Traumatic brain injury, a known risk
factor for AD development [86], can modify the expression
of proinﬂammatory cytokines [87].
LDLR. Low density lipoprotein receptor is implicated in
cholesterol metabolism via endocytosis. Recently, it has been
discovered that overexpression of brain LDLR is associatedInternational Journal of Alzheimer’s Disease 5
with decrease in APOE levels and beta amyloid due to either
inhibited deposition or enhanced clearance [88]. Moreover,
two members of the LDLR family were found to modulate
APP traﬃcking [89]. The LDLR gene is localized to chromo-
some 19. Its association with LOAD was explored in twelve
studies [32, 52, 90–99]. A polymorphism (rs 5930) showed a
consistentassociationwithLOAD(N minor=1,228;OR0.85
95% CI: 0.72–0.99). Zou et al. reported a sex modulation of
LDLR gene that was linked to LOAD in male subgroup [99].
CST3. Cystatin C, a potent inhibitor of lysosomal pro-
teinases, was shown to bind beta amyloid and to prevent
beta-amyloid aggregation and deposition in mouse models
[100]. More recently, cystatin levels have been positively cor-
related with beta-amyloid and tau protein in cerebrospinal
ﬂuid of individuals with AD, mild cognitive impairment,
and healthy controls [101]. The gene-encoding cystatin,
chromosome 20 (CST3), was associated with dementia in
Lewybodydisease.TheassociationbetweenCST3andLOAD
w a sa n a l y z e di nf o u rt e e nC a u c a s i a n[ 32, 52, 72, 96, 102–111]
and four Asian studies [112–115]. Overall Caucasian sample
included 2,502 patients and 1,897 controls. Overall Asian
sample included 814 patients and 1,293 controls. Two CST3
polymorphisms were associated with LOAD in Caucasian
groups.Thebestoneisrs1064039(N minor =1,203;OR1.16
95% CI: 1.00–1.33).
CHRNB2. EachnAChRproteinismadeupofacombination
of ﬁve subunits, usually two alpha (α) and three beta (β)
subunits. Many diﬀerent combinations are possible, and the
characteristics of each nAChR protein depend on which
subunits it contains. In the brain, nAChR proteins most
commonly consist of two α4 subunits and three β2 subunits.
The CHRNB2 gene (chromosome 1) is responsible for
producing the β2 subunit. A wide range of brain functions
depend on nAChR channels, including sleep and arousal,
fatigue, anxiety, attention, pain perception, and memory.
The channels are also active before birth, which suggests that
theyareinvolvedinearlybraindevelopment.Theassociation
between CHRNB2 and LOAD was originally investigated in
an Asian sample of 58 patients and 51 controls with negative
results [116]. Three Caucasian studies followed the ﬁrst one
[117–119]. Cook et al. analyzed three samples and reported a
signiﬁcant association with LOAD (N minor = 227; OR 0.69
95% CI: 0.51–0.95).
SORCS1. S o r C Sp r o t e i n s( l i k eS o r L A )a r em e m b e r so ft h e
Vps10p family of sorting receptors. SorCS1 binds to nerve
growth factor (NGF) propeptide. Pro-NGF is increased in
AD brains, and its binding to neurotrophin receptor p75
induces apoptotic cell death in neurons [120]. In addition,
SorCS1 was involved in APP processing [121]. The gene-
encoding SorCS1, SORCS1 (chromosome 10), has been
associated with insulin signaling and diabetes mellitus [122].
Grupe et al. [77] reported an association between SORCS1
and LOAD in four Caucasian samples (rs600879; N minor
= 567; OR 1.34 95% CI: 1.09–1.65). A family-based study
showed an association between SORCS1 and LOAD in a
women subgroup [123].
TNF. Tumor necrosis factor alpha induces the production of
betaamyloid[9],anditincreasestheriskofdevelopingADin
cognitively intact elderly subjects [124]. The gene-encoding
TNF (chromosome 6) has been extensively investigated as
a susceptibility AD gene. One SNP (rs4647198) was signiﬁ-
cantlyassociatedwithLOADinAsianpopulations[125–127]
(N minor = 301; OR 1.37 95% CI: 1.05–1.08). Increase in
the serum levels of TNF-alpha following acute inﬂammatory
events was found to correlate with a 2-fold increase in the
rate of cognitive decline over a 6-month period in AD
patients. In addition, the rate of cognitive decline was four
fold increased in patients with high basal levels of TNF-
alpha [128]. Etanercept, a biological antagonist of TNF-
alpha, is under evaluation as a therapeutic agent for AD. A
rapid improvement in cognitive performance was reported
following etanercept administration in a pilot study [129].
CCR2. Chemokine receptor 2 is IL-8 receptor. It is coupled
with MAP-kinase pathway to modulate signaling transduc-
tion. CCR2 gene (chromosome 3) was associated with LOAD
in Caucasian samples [32, 130, 131] (rs1799864; N minor =
308; OR 0.73 95% CI: 0.56–0.97).
3.2. Shared Biological Pathways. Gene ontology analysis
identiﬁed 146 GO terms more represented in test dataset
(LOAD genes) than in UniProtKb collection (P<0.001).
Most of them were excluded or collapsed based on criteria
reported above. The following terms were selected: “immune
system process” (TNF, IL8, CR1, CLU, CCR2, PICALM, and
CHRNB2); “vesicle-mediated transport” (PICALM, SORL1,
APOE, BIN1, LDLR, and CLU); “cellular membrane orga-
nization” (SORL1, APOE, PICALM, BIN1, and LDLR);
“alcohol metabolic process” (CHRNB2, SORL1, APOE, TNF,
and LDLR); “lipid transport” (SORL1, APOE, LDLR, CLU,
and TNF); “steroid metabolic process” (SORL1, APOE, TNF,
and LDLR); “cholesterol metabolic process” (APOE, CLU,
LDLR, and SORL1); “cell death/apoptosis” (APOE, TNF, and
CLU); “cell migration” (IL8, APOE, and TNF).
4. Discussion
The genetics of late-onset AD is a complex one. More than
six-hundred genes have been investigated as susceptibility
factors. They represent 2.9% of all genes with known func-
tion (http://www.geneontology.org/). This review focused
on ﬁfteen genes that have been consistently associated with
LOAD in recent years. Such genes, however, participate in
multiple functions, and it is diﬃcult to discriminate which
are pathophysiologically meaningful. Gene ontology (GO) is
a synoptic way to annotate all functions amenable to a single
gene or gene product. We performed a GO analysis of afore-
mentioned genes to identify biological pathways common to
all or most of them. In doing so, we discovered that those
genesconvergedontofewpathwaysthatarediscussedbelow.
4.1. Cholesterol Metabolism. Five genes of our compilation
(APOE; LDLR; SORL1; CLU; TNF) were implicated in
lipid metabolism (four in cholesterol metabolism). This
is consistent with epidemiological ﬁndings that show how
having high cholesterol levels in midlife is a risk factor6 International Journal of Alzheimer’s Disease
for developing AD in late life [132]. Beta amyloid is an
intrinsically disordered protein (IDP) that lacks a well-
deﬁned 3D structure, but it undergoes a series of lipid-
dependent conformational changes in membrane bilay-
ers. Membrane-bound monomers are transformed into
oligomers of varying toxicity rich in beta-sheet structures
(annular pores; amyloid ﬁbrils) or in alpha-helix structures
(transmembrane channels) [133]. Condensed membrane
nano- or microdomains (lipid rafts) formed by sphingolipids
and cholesterol are privileged sites for the binding and
oligomerisation of amyloidogenic proteins. By controlling
the balance between unstructured monomers and α or β
conformers (the chaperone eﬀect), sphingolipids can either
inhibit or stimulate the oligomerisation of amyloidogenic
proteins [134]. Cholesterol has a dual role: regulation of
protein-sphingolipid interactions through a ﬁne tuning of
sphingolipid conformation (indirect eﬀect) and facilitation
of pore (or channel) formation through direct binding
to amyloidogenic proteins [134]. In view of a key role
of cholesterol in beta-amyloid neurotoxicity, statins are
currently under evaluation as potentially eﬀective treatment
for AD. Recently, a meta-analysis of three randomized trials
have yielded negative results [135].
4.2. Vesicle-Mediated Transport/Endocytosis. A second-
pathway was endocytosis. This is supported by ﬁve genes
(PICALM; SORL1; APOE; BIN1; LDLR), and it appears
to be involved in APP traﬃcking. Alterations in the
intracellular transport of APP can directly inﬂuence whether
APP undergoes α-secretase enzymatic activity, releasing a
nontoxic peptide, α-secretase-cleaved soluble APP (sAPPα),
or follows β-secretase and γ-secretase enzymatic pathways,
leading to generation of the neurotoxic forms of beta
amyloid. While the α-secretase enzymes are found at the
cell surface, β-secretase lies within the Golgi apparatus and
endosomes, the γ-secretase complex in the endoplasmic
reticulum, lysosomes, and the cell surface. When APP is
moved into the endosome, it is cleaved by β-secretase and
then transported either to the cell surface or to the lysosome
to be further processed by γ-secretase to form beta amyloid.
However, when APP accumulates at the cell surface, it has
a greater chance of interacting with α-secretase to form
nonamyloid-forming sAPPα [136, 137].
4.3. Immune System. Seven genes (TNF; IL8; CR1; CLU;
CCR2; PICALM; CHRNB2) were found to interfere with
the immune system. Neuroinﬂammation is considered to
be a downstream consequence of amyloidogenesis. Beta-
amyloid deposition within the CNS would bring about
the activation of microglia and thus initiate a proinﬂam-
matory cascade leading to release potentially neurotoxic
substances (cytokines; chemokines; reactive oxygen and
nitrogen species; proteolytic enzymes) and to amplify neural
damage [138]. It has also been suggested that activated
microglia may lead to phosphorylation of tau and formation
of neuroﬁbrillary tangles [139, 140]. Based on inﬂamma-
tory damage, a number of randomized trials compared
the eﬃcacy of nonsteroidal anti-inﬂammatory drugs and
COX inhibitors as antidementia treatments but they yielded
negative results [141]. Inﬂammatory cells can also mediate
the clearance of beta amyloid via phagocytosis [142, 143].
Thishassuggestedthatincreasedproinﬂammatorycytokines
andactivatedmicrogliainADpatientsmaybecompensatory
for defective clearance of beta amyloid on one hand, and this
inﬂammatory cascade may cause brain damage on the other
hand[144].OtherpathwaysemergingfromGOanalysiswere
less frequently discussed. Five genes were implicated in alco-
hol metabolism. The relationship between alcohol consump-
tion and dementia is dose dependent. Alcohol abuse was
associatedwithincreasedprevalenceofcognitivedysfunction
in the elderly, whereas a daily alcohol consumption of less
than40gforwomenand80gformenwasprotectiveagainst
cognitive impairment [145]. The protective eﬀect of mod-
erate drinking was conﬁrmed in prospective studies [146].
Instead, heavy drinking usually leads to cognitive disorders,
but brain lesions [147] as well as cognitive deﬁcits [148–150]
are diﬀerent in alcohol-related dementia and AD. APOE was
found to modulate the link between alcohol and AD [151].
In particular, the impact of alcohol on brain appears to be
more detrimental in APOE epsilon4 carriers [152, 153].
4.4. Genetic Networks. These pathways are actually inter-
connected. One such network is lipoprotein-inﬂammation
apoptosis. Central links in this chain are APOE and CLU.
Animal models have shown the inﬂuence of APOE alle-
les on proinﬂammatory cytokine (TNF-alpha; IL-6; IL-1)
expression and sepsis [154–156]. Recently, we have reported
an association between APOE alleles and IL-1beta levels in
patients with AD [157]. Apolipoprotein E has a protective
eﬀect against apoptosis which is signiﬁcantly reduced in the
presenceofthepathogenicepsilon4isoform[158].Clusterin
that is involved in cholesterol metabolism (it is also named
apolipoprotein J) and the regulation of complement cascade
is known to block apoptosis by binding to proapoptotic
mediator Bax and sequestering it in the cytoplasm, thereby,
preventing Bax-triggered mitochondrial apoptosis [159]. A
second network is centered around intracellular transport of
APP, and macroautophagy intracellular transport is medi-
ated by endocytic pathway. Sorting of internalized molecules
occurs in the early endosome, which directs the material
back to the plasma membrane for recycling, to the trans-
Golgi network for further processing, or to late endosomes
and lysosomes for degradation. APP potentially undergoes
processing at each of these locations. Early endosomes
produceAβfromAPPinnormalcellsandmediatetheuptake
of Aβ and soluble APP [160]. Beta-amyloid localization to
enlargedendosomesisprominentinearlydevelopmentalAD
[161, 162]. Macroautophagy is a constitutively active branch
of the wider endosome-autophagosome-lysosome system,
involved in the sequestration of cytosolic regions into char-
acteristic double-membrane or multimembrane autophago-
somes that are delivered to lysosomes for degradation [163].
MacroautophagyinterfereswithdiﬀerentstagesofAPP-beta-
amyloid cycle, and it aﬀects both APP proteolysis to beta
amyloid [164] and lysosomal proteolysis in postsecretase
APPcatabolism[165].Autophagicvacuoleareidentiﬁableby
theprotein,LC3-II(phospho-lipidatedformofmicrotubule-
associated protein 1 light chain 3-I, MAP1 LC3-I), whichInternational Journal of Alzheimer’s Disease 7
is associated with both luminal and cytosolic surfaces of
vacuole membranes [163]. Classical autophagy activation
is regulated through PI3K/Akt/mTOR pathways although
alternative mTOR-independent pathways also exist [166].
The endocytic and autophagy pathways converge onto the
lysosom system. Beta amyloid is generated in multivesicular
bodies of the endosomal pathway and may also be generated
inautophagosomes[167].Inrecentyears,severalgenescould
be linked to LOAD from large genome-wide association
studies (GWASs) [168]. However their eﬀect sizes are
small (OR 1.20–1.66), consistent with those reported for
other neuropsychiatric disorders [169], and most genetic
variability is still unexplained. Using a method similar to
the present one, authors clustered functionally interrelated
genes, and they tested such networks in ninety-six heritable
disorders. This allowed to detect at least one disease gene in
54% of the loci studied, representing a 2.8% increase over
randomselectionofcandidategenes[170].Thissuggeststhat
reconstructing shared functional pathways may signiﬁcantly
reduce the cost and eﬀort of pinpointing true disease genes
in disorders for which multiple susceptibility loci have been
reported. On the other hand, analyzing complex networks of
genes that are altered in AD patients by means of genomics
orproteomics,itispossibletodissectthemintoclusters,each
associated with a speciﬁc biological pathway. Such clusters
could then be investigated in single patients with AD who
are pathophysiologically heterogeneous although they share
the same diagnostic label. This would provide more suitable
targets for AD treatment.
4.5. Secondary Genetic Eﬀects. Several characteristics of AD
patients, not merely diagnostic identiﬁcation, are aﬀected
by AD genes [86]. These secondary eﬀects should be
incorporated to reﬁne genetic networks. A well-known
epidemiological ﬁnding is that AD is more prevalent in
women [171,172]althoughauthorshavecontendedthatthis
could be an age eﬀect [1]. A connection may exist between
gender and APP traﬃcking. In fact, a few studies have
shown that the association of sorting protein genes SORL1
and SORCS1 with LOAD was limited to women [67, 75,
123]. Similarly, a few haplotypes of LDLR polymorphisms
were more represented in AD patients and associated with
altered biomarkers (CSF Abeta(42); tau protein) in women
[98]. Notably, estrogen increases APP transport within the
trans-Golgi network [173]. A large subset of patients with
AD (60%–80%) have neuropsychiatric symptoms such as
depression, agitation, and psychosis (behavioral and psy-
chiatric symptoms of dementia, BPSD) [174, 175]. These
disturbancesareassociatedwithworseprognosis,morerapid
cognitive decline, higher costs of care, increased caregiver
burden and earlier nursing home placement. Proinﬂamma-
tory cytokines may play a signiﬁcant role in BPSD. In fact,
the C-511T polymorphism in the promoter region of the
IL-1 beta gene was found to correlate with depressive and
psychotic symptoms in AD patients [176, 177]. Similarly,
a IL-1alpha SNP (rs1800587) was associated with AD-
related depression [178]. Genetic variations at SORL1 may
be associated with AD-related psychosis as well although this
is still controversial. In fact, one published study revealed
no association between SORL1 polymorphisms and AD
psychosis [179]. On the contrary, we found that SNPs 8–
10 were associated with psychotic manifestations in AD
patients [75]. Among possible endophenotypes, SORL1 was
associated with a selective deﬁcit in abstract reasoning
[180] and MRI changes [60]. Other genes have been less
extensively investigated. CST3 was found to correlate with
age of onset in sporadic AD [181]a sw e l la sE E Ga l t e r a t i o n s
in subjects with AD and mild cognitive impairment [182].
Plasma clusterin concentrations were associated with brain
atrophy, severity of Alzheimer’s disease, and rate of clinical
progression although there was no eﬀect of CLU SNPs on
gene and protein expression [36].
4.6. Gene-Gene Interactions and Epigenetics. Gene-gene
interactions may account for a substantial genetic variability
in LOAD. Gene-gene interactions were reported between IL6
andIL10[183],IL6 andA2M [184],andIL1AandIL8.APOE
wasfoundtointeractwithgenesencodingmethylenetetrahy-
drofolate reductase (MTHF)[ 185], luteinizing hormone
receptor [186], and angiotensin-converting enzyme (ACE)
[187]. To increase the number of gene-gene interactions, a
useful approach could be to investigate genetic networks that
are based on homogeneous biological pathways. Epigenetic
modiﬁcations alter the structure of chromatin to inﬂuence
gene expression. A common epigenetic pathway is DNA
methylation. This occurs naturally on cytosine bases at CpG
sequences, and it is usually associated with triggering histone
deacetylation, chromatin condensation, and gene silencing.
Diﬀerentially methylated cytosines give rise to distinct
patternsspeciﬁcforeachtissuetypeanddiseasestate.Among
AD genes, PSEN1, APP, and APOE have abundant CpG
sites and are signiﬁcantly aﬀected by methylation [188].
Decrements in markers of DNA methylation were consis-
tently reported in AD neurons and could explain discordant
AD onset in twin pairs [189]. Developmental exposure to
xenobiotics such as lead (Pb) inﬂuences methylation in AD
genes, and this would predispose to AD later in life [190].
4.7. Pharmacogenomics. Response to antidementia drugs
is also aﬀected by genetic factors. Pharmacogenomics in
AD is still in its infancy, with genes associated with AD
pathogenesis and genes responsible for drug metabolism
(cytochrome P450) [191]. In monogenic-related studies,
APOE-4/4 carriers are the worst responders. In trigenic
(APOE-PS1-PS2 clusters)-related studies, the best respon-
ders are those patients carrying the 331222-, 341122-,
341222-,and441112-genomicproﬁles.Theworstresponders
in all genomic clusters are patients with the 441122+ geno-
type. This would indicate a powerful eﬀect of APOE geno-
types on therapeutics in networking activity with other AD-
related genes converging on the same biological pathways.
5. Conclusions
This review was based on the most comprehensive collection
of published studies about the genetics of AD. The best
genes were classiﬁed according to qualitative criteria such as
size of research samples, heterogeneity across studies, and8 International Journal of Alzheimer’s Disease
control for various sources of bias including small eﬀect
size (OR) and publication bias. However, there were also
important limitations, mainly due to Alzgene design. First,
meta-analyses were restricted to allele contrast, which is less
powerful than genotype-based test and allows no inference
of the true underlying mode of inheritance, and there
was no genetic information at haplotype level. Moreover,
only the main eﬀect was investigated, that is diagnostic
association with AD, while other clinical phenotypes and
endophenotypes could not be considered alongside gene-
gene and gene-environment interactions. On the contrary, a
nonnegligible eﬀect of LOAD genes may be directed to these
secondary targets as suggested elsewhere. Gene ontologies
were developed to provide a shared representation of genes
a n dg e n ep r o d u c t sa c r o s ss p e c i e s .G Ot e r m sc o n t a i nb r o a d
deﬁnitions of biological processes in the living cell. Hence,
these terms are suitable to identify areas for genomic explo-
ration (e.g., all genes implicated in cholesterol metabolism)
but not to elucidate pathogenic mechanisms in depth.
Notwithstanding these caveats including all published
studies in a single open-access database (Alzgene) highlights
the most important pathophysiological mechanisms, which
show the convergence of many genes, and it more easily
prompts new biological hypotheses.
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